List of Excipients in Branded Drug EVEROLIMUS

Generic Drugs Containing EVEROLIMUS

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	everolimus	0054-0470	ANHYDROUS LACTOSE
Hikma Pharmaceuticals USA Inc	everolimus	0054-0470	BUTYLATED HYDROXYTOLUENE
Hikma Pharmaceuticals USA Inc	everolimus	0054-0470	CROSPOVIDONE
Hikma Pharmaceuticals USA Inc	everolimus	0054-0470	HYPROMELLOSE 2910
Hikma Pharmaceuticals USA Inc	everolimus	0054-0470	MAGNESIUM STEARATE
Hikma Pharmaceuticals USA Inc	everolimus	0054-0480	ANHYDROUS LACTOSE
Hikma Pharmaceuticals USA Inc	everolimus	0054-0480	BUTYLATED HYDROXYTOLUENE

What are the Most Frequently-Used Excipients in EVEROLIMUS?

# Of NDCs	Excipient
2	ACETONE
19	ANHYDROUS LACTOSE
20	BUTYLATED HYDROXYTOLUENE
2	CELLULOSE, MICROCRYSTALLINE
2	CROSCARMELLOSE SODIUM
20	CROSPOVIDONE
3	HYPROMELLOSE

Everolimus Excipient Strategy, Formulation Patents, and Commercial Opportunities

Last updated: August 6, 2026

Everolimus is an established, poorly water-soluble mTOR inhibitor marketed in multiple oral dosage forms, including Afinitor, Afinitor Disperz, Votubia, Zortress and generic tablets. The core molecule is broadly genericized in the United States, but commercial opportunities remain in pediatric dispersible products, taste-masked formulations, bioavailability enhancement, transplant adherence, manufacturing efficiency and differentiated drug delivery.

The most defensible excipient strategy is not a simple tablet-cost reduction. It is a platform that improves wetting, dispersion, dose flexibility, palatability, stability or bioequivalence without creating a new clinical or regulatory burden.

What excipients are used in approved everolimus products?

Approved everolimus products use conventional solid-dose excipients, with lactose-based tablet matrices and superdisintegrants as the principal formulation tools.

Product	Active ingredient	Dosage form	Reported excipient classes	Primary formulation objective
Afinitor	Everolimus	Immediate-release tablet	Lactose monohydrate, hypromellose, crospovidone, magnesium stearate; colorants vary by strength	Oral solid dosage and dose strength differentiation
Afinitor Disperz	Everolimus	Dispersible tablet	Lactose monohydrate, hypromellose, crospovidone, magnesium stearate and other strength-dependent excipients	Dispersion in water for pediatric or swallowing-impaired patients
Votubia	Everolimus	Tablet and dispersible tablet	Lactose-containing matrix, hypromellose, crospovidone, magnesium stearate and strength-specific excipients	European and international equivalent of the Afinitor platform
Zortress	Everolimus	Immediate-release tablet	Lactose monohydrate, hypromellose, crospovidone, magnesium stearate and colorants	Transplant immunosuppression
Generic everolimus	Everolimus	Tablet	Product-specific combinations of diluents, binders, disintegrants, lubricants and pigments	Bioequivalent substitution

The FDA labeling for Afinitor, Afinitor Disperz and Zortress identifies the product-specific inactive ingredients and provides the principal reference point for excipient benchmarking (Novartis Pharmaceuticals Corporation, 2023a, 2023b, 2023c).

Everolimus has low aqueous solubility and is a substrate for CYP3A4 and P-glycoprotein. Excipients that alter gastrointestinal wetting, dispersion, precipitation or intestinal permeability can affect exposure. Any formulation change therefore requires tight control of dissolution and pharmacokinetic comparability.

Which excipients are technically important?

Crospovidone is central to rapid tablet breakup. Hypromellose provides binding and matrix control but can slow wetting at higher levels. Lactose monohydrate supplies bulk and compressibility. Magnesium stearate supports manufacturability but excessive lubrication can reduce tablet wettability and dissolution.

The most commercially relevant excipient variables are:

1. Particle size and grade of lactose.
2. Crospovidone level and intragranular versus extragranular placement.
3. Hypromellose viscosity and concentration.
4. Magnesium stearate mixing time and specific surface area.
5. Granulation moisture and compression force.
6. Excipient compatibility with low-dose uniformity requirements.

What formulation challenges does everolimus create?

Everolimus presents four principal formulation risks: poor aqueous solubility, low-dose content uniformity, food-effect sensitivity and exposure variability.

Solubility and dissolution

Everolimus is a hydrophobic macrolide. Conventional immediate-release tablets can achieve adequate exposure, but dissolution remains sensitive to particle size, wetting and process conditions. A formulation that improves apparent solubility may also change absorption rate or peak concentration.

Potential approaches include:

• Micronized or nanomilled everolimus.
• Surfactant-assisted wetting.
• Amorphous solid dispersions.
• Lipid-based self-emulsifying systems.
• Polymer precipitation inhibitors.
• Porous or spray-dried carrier systems.
• Co-processed excipients designed for rapid disintegration.

Each approach creates a different regulatory profile. A simple micronization or excipient-grade change may fit an abbreviated pathway if comparative dissolution and bioequivalence are adequate. An amorphous dispersion or lipid system may require more extensive characterization because supersaturation, precipitation and food effects can change.

Low-dose uniformity

Transplant dosing commonly uses 0.25 mg, 0.5 mg and 0.75 mg strengths, while oncology products use 2 mg, 5 mg, 7.5 mg and 10 mg strengths. The lower strengths create a higher risk of content-uniformity failure because the active represents a small fraction of tablet mass.

Commercially useful excipient technologies include:

• Ordered mixtures that improve drug distribution.
• Carrier-based premixes.
• Spray-dried drug-excipient composites.
• Low-shear blending processes.
• Segregation-resistant granules.
• Mini-tablet or multiparticulate platforms.

The strongest opportunity is a manufacturing platform that improves low-dose uniformity without changing the dissolution profile.

Taste and mouthfeel

Afinitor Disperz and Votubia dispersible tablets are intended for dispersion in water. Pediatric patients may reject the product because of bitterness, residual particles or unpleasant mouthfeel. A taste-masking strategy could use polymer coating, ion-exchange complexation, lipid barriers or multiparticulate encapsulation.

Taste masking must preserve rapid release after swallowing. Excessive coating can create delayed release, incomplete dose recovery in the dosing cup or inconsistent exposure. The most practical product opportunity is a low-volume, rapidly dispersible, palatable presentation with validated dose recovery from the administration vessel.

What formulations are protected by everolimus patents?

The original everolimus compound and early formulation patents have largely reached or passed their ordinary U.S. patent terms. Current competitive protection is more likely to arise from specific formulation, manufacturing, combination or method-of-use claims than from broad composition-of-matter rights.

Protection category	Relevance to everolimus	Commercial status
Everolimus compound claims	Historically protected the active ingredient and rapamycin derivative chemistry	Broad protection is generally expired or commercially weakened
Immediate-release tablet claims	May cover excipient ratios, particle size, granulation or dissolution characteristics	Potentially relevant only if unexpired and listed or enforceable
Dispersible tablet claims	May cover dispersion behavior, dose administration and pediatric use	Higher strategic value for pediatric products
Method-of-use claims	Oncology, tuberous sclerosis complex, transplant and other indications	Scope depends on claim language and jurisdiction
Manufacturing claims	May cover crystallization, particle engineering, granulation or impurity control	Can create non-Orange-Book barriers
Combination claims	Everolimus with other immunosuppressants or oncology agents	Relevant to selected clinical uses

The FDA Orange Book should be checked at the product and strength level because patent listings can differ between Afinitor, Afinitor Disperz and Zortress. A formulation patent may be listed for one product but not another. The Orange Book also does not capture every potentially relevant manufacturing or process patent (U.S. Food and Drug Administration, 2024a).

When does everolimus lose exclusivity?

Everolimus has already lost the primary exclusivity associated with the original branded products in the United States. The market is therefore defined by generic competition, indication-specific labeling, residual patents and formulation differentiation.

Milestone	Product or pathway	Commercial significance
2009	FDA approval of Afinitor	Established oncology and tuberous sclerosis franchise
2010	FDA approval of Zortress	Established transplant indication
2010	FDA approval of Afinitor Disperz	Added dispersible delivery for selected patients
2010s	International Votubia approvals	Expanded pediatric and European use
Late 2010s onward	Generic everolimus approvals	Reduced reliance on single-source supply
Current	Product-specific patents and regulatory exclusivities	Residual barriers depend on indication and jurisdiction

FDA orphan-drug exclusivity can apply to a specific indication rather than the entire active ingredient. Pediatric exclusivity, if granted, can add six months to eligible patent or regulatory exclusivity. These periods must be assessed from FDA approval records rather than inferred from the original brand launch date (U.S. Food and Drug Administration, 2024b).

Which companies are challenging everolimus products?

Generic manufacturers have challenged the oral tablet market through abbreviated new drug applications. The relevant competitive field includes established generic companies and regional manufacturers that can support controlled-substance-free oral solid dosage production, bioequivalence studies and global regulatory filings.

The principal competitive categories are:

• Generic tablets referencing Afinitor.
• Generic tablets referencing Zortress.
• Generic or multisource products for transplant indications.
• International products referencing Votubia.
• Potential future dispersible or pediatric equivalents.

Paragraph IV litigation risk depends on whether a generic applicant challenges an unexpired listed patent. A Paragraph IV certification can trigger patent litigation and a 30-month stay under the Hatch-Waxman framework if the brand sponsor files suit within the statutory period. Generic applicants can also use Paragraph III certifications or wait for patent expiry.

The critical diligence questions are whether the proposed product references the oncology or transplant product, whether it includes the same dosage strengths, and whether it uses a dispersible presentation. A generic tablet does not automatically create an equivalent competitive threat to a dispersible pediatric product.

What is the FDA regulatory status of everolimus?

Everolimus is FDA-approved in several distinct clinical settings:

• Advanced renal cell carcinoma after failure of sunitinib or sorafenib.
• Progressive neuroendocrine tumors of pancreatic, gastrointestinal or lung origin.
• Renal angiomyolipoma and associated manifestations of tuberous sclerosis complex.
• Subependymal giant cell astrocytoma associated with tuberous sclerosis complex.
• Prevention of organ rejection in selected transplant recipients through Zortress.

Afinitor and Afinitor Disperz are not interchangeable simply because they contain the same active ingredient. Indication, dosage strength, administration instructions, labeling and reference-product designation matter. The FDA Orange Book and FDA product databases should be used to determine therapeutic-equivalence codes and currently approved manufacturers (U.S. Food and Drug Administration, 2024a, 2024c).

What commercial opportunities exist for everolimus excipients?

Pediatric dispersible formulations

The strongest differentiated opportunity is a dispersible formulation that improves:

• Taste.
• Dose recovery.
• Water dispersion time.
• Suspension uniformity.
• Administration volume.
• Storage stability after dispersion.
• Dose flexibility below standard tablet strengths.

A platform that supports 0.1 mg to 1 mg dose increments could address pediatric titration more effectively than conventional fixed-strength tablets. The formulation must avoid clinically meaningful changes in everolimus exposure.

Excipient systems for low-dose manufacturing

A co-processed excipient system can reduce segregation and improve content uniformity in 0.25 mg to 0.75 mg tablets. Suppliers could commercialize a validated carrier system rather than a single excipient. The value proposition is process robustness, lower rejection rates and easier technology transfer.

Solubility-enhancing systems

A spray-dried dispersion, nanocrystal system or self-emulsifying formulation could support new dosage forms or reduce dose size. The business case is stronger where the technology enables a clear benefit, such as lower variability, reduced food effect or a pediatric liquid-like presentation.

Taste-masked multiparticulates

Taste-masked granules, pellets or mini-tablets could support oral administration when patients cannot swallow conventional tablets. This approach may also enable sachets, unit-dose cups or feeding-tube administration, subject to compatibility and dose-recovery testing.

Stability and packaging

Everolimus products require protection against moisture, light and process-related degradation. Opportunities include:

• High-barrier blister films.
• Desiccant-integrated packaging.
• Low-moisture excipient grades.
• Oxygen-scavenging systems where justified.
• Unit-dose packaging for transplant adherence.
• Packaging that separates tablets from reconstituted liquids.

Packaging patents may provide a more practical differentiation route than broad excipient claims.

How strong is the everolimus patent estate?

The everolimus patent estate is commercially weaker at the active-ingredient level and more defensible at the product-specific level.

Estate component	Relative strength	Reason
Core active-ingredient patents	Low	Long commercial history and expired foundational rights
Standard immediate-release tablets	Low to moderate	Generic substitution and conventional excipients limit differentiation
Dispersible pediatric products	Moderate	Administration, palatability and dose-recovery claims may remain useful
Novel solubility systems	Moderate to high	Potentially patentable composition and process space
Manufacturing and impurity control	Moderate	Can be difficult to design around if process claims are narrow and validated
Method-of-use claims	Moderate	Depends on indication, patient population and label carve-outs
Packaging and adherence systems	Low to moderate	Usually incremental but commercially useful

The patent opportunity is strongest when the excipient platform produces a measurable pharmaceutical effect, not merely a different ingredient list. Claims directed only to replacing lactose with another diluent are likely to be narrower and easier to design around.

What generic entry risks exist for everolimus?

Generic entry risk is high for conventional tablets and lower for differentiated dispersible products.

Immediate-release tablets

Generic companies can usually compete through standard oral solid dosage technology, provided they meet dissolution, assay, uniformity, impurity and bioequivalence requirements. Price erosion is likely to be greatest in high-volume oncology strengths and standard transplant tablets.

Dispersible tablets

The technical and regulatory burden is higher because applicants must demonstrate:

• Rapid and complete dispersion.
• Dose uniformity in the dispersed liquid.
• Stability during the labeled administration window.
• Adequate recovery from the cup or syringe.
• Acceptable particle size and sedimentation behavior.
• Comparable pharmacokinetics where required.
• Pediatric acceptability if the product is positioned for children.

The dispersible segment remains vulnerable to a well-designed generic, but the barrier is higher than for a conventional tablet.

How does everolimus compare with sirolimus?

Everolimus and sirolimus are both mTOR inhibitors, but their excipient and product strategies differ.

Factor	Everolimus	Sirolimus
Main commercial uses	Oncology, tuberous sclerosis complex, transplant	Transplant and selected rare-disease uses
Dosage forms	Tablets and dispersible tablets	Tablets and oral solution
Formulation priority	Rapid dispersion, low-dose uniformity, pediatric administration	Solution stability, taste, dose measurement and oral solid dosage
Generic opportunity	Conventional tablets and dispersible products	Tablets, oral solution and administration systems
Key risk	Exposure variability and food/drug interactions	Solubility, oral-solution handling and taste

Everolimus offers a clearer pediatric dispersible-tablet opportunity. Sirolimus offers stronger opportunities in liquid formulation, packaging and dose-measurement systems.

What patent litigation and settlement issues affect everolimus?

Everolimus litigation exposure should be assessed product by product. The most relevant triggers are:

• Paragraph IV challenges to listed Afinitor or Zortress patents.
• Disputes over whether a generic label induces use for a patented indication.
• Litigation over dispersible-tablet claims.
• Process patent disputes involving particle engineering or impurity profiles.
• Settlement agreements that delay generic launch or permit limited entry.

A standard generic label may carve out a patented method of use. That can preserve liability risk if the manufacturer, distributors or promotional materials encourage the carved-out use. Settlement terms can also differ by strength and reference product.

Public litigation databases, FDA Orange Book updates and ANDA approval records should be reviewed together. No single source provides a complete view of all formulation and process risk.

Key Takeaways

• Everolimus is a mature molecule with high generic-entry risk for conventional tablets.
• Approved products rely on conventional excipients, including lactose monohydrate, hypromellose, crospovidone and magnesium stearate.
• The best excipient opportunities are in pediatric dispersible products, taste masking, low-dose uniformity and solubility enhancement.
• A differentiated excipient system must improve a measurable product attribute while preserving everolimus exposure.
• The core composition-of-matter estate is commercially weak compared with formulation, manufacturing and method-of-use rights.
• Afinitor, Afinitor Disperz and Zortress must be evaluated separately for Orange Book listings, therapeutic equivalence and litigation exposure.
• Generic competition is more immediate for 2 mg, 5 mg, 7.5 mg and 10 mg conventional tablets than for pediatric dispersible presentations.
• Manufacturing know-how, dose recovery and packaging can create commercial barriers even where broad formulation patents are unavailable.

FAQs About Everolimus Excipient and Formulation Opportunities

Can lactose-free everolimus tablets be commercialized?

Yes. A lactose-free formulation can be developed, but it must preserve tablet performance, content uniformity, dissolution and bioequivalence. The commercial rationale is strongest for patients with lactose intolerance or for manufacturers seeking a differentiated label.

Which excipient is best for improving everolimus dissolution?

No single excipient is universally optimal. Crospovidone can improve tablet breakup, while surfactants, particle engineering and polymeric dispersion systems may improve wetting or apparent solubility. The preferred technology depends on the target dissolution profile and pharmacokinetic requirements.

Is a pediatric liquid everolimus formulation commercially attractive?

Yes. A liquid or reconstitutable formulation could improve administration for young children and patients with swallowing difficulty. The main development risks are dose uniformity, chemical stability, sedimentation, taste, container compatibility and accurate dosing.

Can a new everolimus excipient combination receive patent protection?

Potentially. Patentability is stronger when the combination produces an unexpected technical effect, such as improved stability, reduced food effect, superior dose recovery or a defined dissolution advantage. A routine substitution of one diluent for another is less likely to create strong protection.

Are everolimus and sirolimus excipients interchangeable?

No. Both are hydrophobic mTOR inhibitors, but their dose levels, dissolution behavior, pharmacokinetics and approved dosage forms differ. Excipient choices must be supported by product-specific compatibility, dissolution and bioequivalence data.

References

1. Novartis Pharmaceuticals Corporation. (2023a). Afinitor (everolimus) tablets, prescribing information. U.S. Food and Drug Administration.

2. Novartis Pharmaceuticals Corporation. (2023b). Afinitor Disperz (everolimus) tablets for oral suspension, prescribing information. U.S. Food and Drug Administration.

3. Novartis Pharmaceuticals Corporation. (2023c). Zortress (everolimus) tablets, prescribing information. U.S. Food and Drug Administration.

4. U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.

5. U.S. Food and Drug Administration. (2024b). Drugs@FDA: FDA-approved drugs database. U.S. Department of Health and Human Services.

6. U.S. Food and Drug Administration. (2024c). Electronic Orange Book patent and exclusivity information. U.S. Department of Health and Human Services.